ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
FDA approves bioidentical hormone therapy for menopausal hot flashes
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 127386" data-attributes="member: 3"><p>This treatment has been available via compounding pharmacies for years.</p><p></p><p>The FDA has approved the first bioidentical hormone therapy combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause, TherapeuticsMD announced in a press release.</p><p></p><p>The approval of the bioidentical estradiol and progesterone capsules (Bijuva), follows results from the phase 3 REPLENISH trial, first presented at the Endocrine Society annual meeting in April 2017 and reported by Endocrine Today, which demonstrated that a combination of 17beta-estradiol and progesterone appears to be safe and effective for reducing hot flash frequency and severity in menopausal women with a uterus.</p><p></p><p>“The approval of Bijuva represents an important and new opportunity for menopausal women suffering from moderate to severe vasomotor symptoms,” Brian Bernick, co-founder and director of TherapeuticsMD, said in the release. “Menopausal women and their health care providers have been seeking bioidentical combination therapies for many years without an FDA-approved option.”</p><p></p><p><a href="https://www.healio.com/endocrinology/reproduction-androgen-disorders/news/online/%7B650300ef-4951-4c7b-b824-fc3546099fd1%7D/fda-approves-bioidentical-hormone-therapy-for-menopausal-hot-flashes" target="_blank">FDA approves bioidentical hormone therapy for menopausal hot flashes</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 127386, member: 3"] This treatment has been available via compounding pharmacies for years. The FDA has approved the first bioidentical hormone therapy combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause, TherapeuticsMD announced in a press release. The approval of the bioidentical estradiol and progesterone capsules (Bijuva), follows results from the phase 3 REPLENISH trial, first presented at the Endocrine Society annual meeting in April 2017 and reported by Endocrine Today, which demonstrated that a combination of 17beta-estradiol and progesterone appears to be safe and effective for reducing hot flash frequency and severity in menopausal women with a uterus. “The approval of Bijuva represents an important and new opportunity for menopausal women suffering from moderate to severe vasomotor symptoms,” Brian Bernick, co-founder and director of TherapeuticsMD, said in the release. “Menopausal women and their health care providers have been seeking bioidentical combination therapies for many years without an FDA-approved option.” [URL="https://www.healio.com/endocrinology/reproduction-androgen-disorders/news/online/%7B650300ef-4951-4c7b-b824-fc3546099fd1%7D/fda-approves-bioidentical-hormone-therapy-for-menopausal-hot-flashes"]FDA approves bioidentical hormone therapy for menopausal hot flashes[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
FDA approves bioidentical hormone therapy for menopausal hot flashes
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top